Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Limin Tang, Min Sha, Ting Guo, Huimin Lu, Jingyu Qian, Qixiang Shao & Jun Ye. (2023) Expression and Clinical Significance of TIGIT in Primary Breast Cancer. International Journal of General Medicine 16, pages 2405-2417.
Read now
Read now
Kate Rittenhouse-Olson. (2020) Letter from the Editor 2020: Annual Summary and Introduction of the Thematic Issue and Guest Editor. Immunological Investigations 49:7, pages 687-691.
Read now
Read now
Mostafa Khedri, Khalil Abnous, Houshang Rafatpanah, Maryam Sadat Nabavinia, Seyed Mohammad Taghdisi & Mohammad Ramezani. (2020) Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach. Immunological Investigations 49:5, pages 535-554.
Read now
Read now
Martin Perez-Santos, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta & Lourdes Millán-Pérez Peña. (2020) Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536. Expert Opinion on Therapeutic Patents 30:2, pages 83-86.
Read now
Read now
Kate Rittenhouse-Olson. (2019) Thematic 2019 Letter from the Editor. Immunological Investigations 48:7, pages 673-679.
Read now
Read now
Daoyuan Li, Siyi Hu, Qinglin Fan, Wenying Bao, Wei Zhou, Ting Xu, Taohong Ye, Hao Liu & Lihua Song. (2019) Phage display screening of TIGIT-specific antibody for antitumor immunotherapy. Bioscience, Biotechnology, and Biochemistry 83:9, pages 1683-1696.
Read now
Read now
. (2018) Thematic 2018 Letter from the Editor. Immunological Investigations 47:8, pages 765-769.
Read now
Read now
Alice L. Hung, Russell Maxwell, Debebe Theodros, Zineb Belcaid, Dimitrios Mathios, Andrew S. Luksik, Eileen Kim, Adela Wu, Yuanxuan Xia, Tomas Garzon-Muvdi, Christopher Jackson, Xiaobu Ye, Betty Tyler, Mark Selby, Alan Korman, Bryan Barnhart, Su-Myeong Park, Je-In Youn, Tamrin Chowdhury, Chul-Kee Park, Henry Brem, Drew M. Pardoll & Michael Lim. (2018) TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology 7:8.
Read now
Read now
Wenjie Guo, Sihan Liu, Xiaoli Zhang, Yating Chen, Ruolan Qian, Ziyuan Zou, Xin Chen & Peng Luo. (2017) The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. Drug Design, Development and Therapy 11, pages 3367-3376.
Read now
Read now
. (2017) Letter from the Editor 2017. Immunological Investigations 46:8, pages 759-764.
Read now
Read now
Haitao Ma, GuoCai Mao, GuangBo Zhang & HaiTao Huang. (2017) The Expression and Clinical Signification of PD-1 in Lymph Nodes of Patients with Non-small Cell Lung Cancer. Immunological Investigations 46:7, pages 639-646.
Read now
Read now
Articles from other publishers (24)
Anna Pawłowska, Anna Rekowska, Weronika Kuryło, Anna Pańczyszyn, Jan Kotarski & Iwona Wertel. (2023) Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 24:13, pages 10859.
Crossref
Crossref
Dinghu Weng, Rong Guo, Ziyang Zhu, Yu Gao, Rui An & Xiuman Zhou. (2023) Peptide-based PET imaging agent of tumor TIGIT expression. EJNMMI Research 13:1.
Crossref
Crossref
Chenming Guo, Zhiwen Luo, Dilimulati Ismtula, Xiaojuan Bi, Han Kong, Yiyang Wang, Zhen Yang & Xinmin Mao. (2023) TIGIT as a Novel Prognostic Marker for Immune Infiltration in Invasive
Breast Cancer. Combinatorial Chemistry & High Throughput Screening 26:3, pages 639-651.
Crossref
Crossref
Anna Pawłowska, Wiktoria Skiba, Dorota Suszczyk, Weronika Kuryło, Joanna Jakubowicz-Gil, Roman Paduch & Iwona Wertel. (2022) The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients. Cancers 14:23, pages 5757.
Crossref
Crossref
Zhaoyun Liu, Yixuan Guo, Lei Huang, Yue Jia, Hui Liu, Fengping Peng, Lixiang Duan, Hongkai Zhang & Rong Fu. (2022) Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes. Cell Communication and Signaling 20:1.
Crossref
Crossref
Lu Yu, Minghan Sun, Qi Zhang, Qiao Zhou & Yi Wang. (2022) Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Shu Rui, Xiangyu Kong, Jiaye Liu, Liying Wang, Xiaofei Wang, Xiuhe Zou, Xun Zheng, Feng Ye, Heng Xu, Zhihui Li & Han Luo. (2022) The landscape of TIGIT target and clinical application in diseases. MedComm – Oncology 1:2.
Crossref
Crossref
Juan Wang, Hongyan Hou, Lie Mao, Feng Wang, Jing Yu, Ying Luo, Qun Lin & Ziyong Sun. (2022) TIGIT Signaling Pathway Regulates Natural Killer Cell Function in Chronic Hepatitis B Virus Infection. Frontiers in Medicine 8.
Crossref
Crossref
Yihui Song, Min Zhao, Huiqing Zhang & Bin Yu. (2022) Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacology & Therapeutics 230, pages 107966.
Crossref
Crossref
Mehrdad Fathi, Inna Pustokhina, Sergey V. Kuznetsov, Mars Khayrullin, Mohammad Hojjat‐Farsangi, Vahid Karpisheh, Ali Jalili & Farhad Jadidi‐Niaragh. (2021) T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life 73:5, pages 726-738.
Crossref
Crossref
Travis Shaffer, Arutselvan Natarajan & Sanjiv S. Gambhir. (2021) PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes. Clinical Cancer Research 27:7, pages 1932-1940.
Crossref
Crossref
Jian-Zhao Xu, Chen Gong, Zheng-Fu Xie & Hua Zhao. (2021) Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma. Frontiers in Oncology 10.
Crossref
Crossref
Q Liang, L Tong, L Xiang, S Shen, C Pan, C Liu & H Zhang. (2021) Correlations of the expression of γδ T cells and their co-stimulatory molecules TIGIT, PD-1, ICOS and BTLA with PR and PIBF in the peripheral blood and decidual tissues of women with unexplained recurrent spontaneous abortion. Clinical and Experimental Immunology 203:1, pages 55-65.
Crossref
Crossref
Qianqian Liang, Lingxia Tong, Liping Xiang, Sujuan Shen, Chenhuan Pan, Cuiping Liu & Hong Zhang. (2020) Distinct changes of in BTLA, ICOS, PD-1, and TIGIT expression on peripheral blood and decidual CD8+ T cells in women with unexplained recurrent spontaneous abortion†. Biology of Reproduction 103:5, pages 1012-1017.
Crossref
Crossref
Marcel P. Trefny, Monika Kaiser, Michal A. Stanczak, Petra Herzig, Spasenija Savic, Mark Wiese, Didier Lardinois, Heinz Läubli, Franziska Uhlenbrock & Alfred Zippelius. (2020) PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunology, Immunotherapy 69:8, pages 1505-1517.
Crossref
Crossref
Danhua Xu, Enhao Zhao, Chunchao Zhu, Wenyi Zhao, Chaojie Wang, Zizhen Zhang & Gang Zhao. (2020) TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer. Immunobiology 225:3, pages 151915.
Crossref
Crossref
Muhammad Khan, Sumbal Arooj & Hua Wang. (2020) NK Cell-Based Immune Checkpoint Inhibition. Frontiers in Immunology 11.
Crossref
Crossref
Qianqian Liu, Jiao Qu, Mingxia Zhao, Qiang Xu & Yang Sun. (2020) Targeting SHP2 as a promising strategy for cancer immunotherapy. Pharmacological Research 152, pages 104595.
Crossref
Crossref
Shiran Hoogi, Vasyl Eisenberg, Shimrit Mayer, Astar Shamul, Tilda Barliya & Cyrille J. Cohen. (2019) A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Andrea Hinsch, Niclas Blessin, Ronald Simon, Martina Kluth, Kristine Fischer, Claudia Hube‑Magg, Wenchao Li, Georgia Makrypidi‑Fraune, Bj�rn Wellge, Tim Mandelkow, Nicolaus Debatin, Doris H�flmayer, Maximilian Lennartz, Guido Sauter, Jakob Izbicki, Sarah Minner, Franziska B�scheck, Ria Uhlig, David Dum, Till Krech, Andreas Luebke, Corinna Wittmer, Frank Jacobsen, Eike Burandt, Stefan Steurer & Waldemar Wilczak. (2019) Expression of the immune checkpoint receptor TIGIT in seminoma. Oncology Letters.
Crossref
Crossref
Liang‑Liang Cai & Jie Wang. (2019) Liquid biopsy for lung cancer immunotherapy (Review). Oncology Letters.
Crossref
Crossref
Niclas C. Blessin, Ronald Simon, Martina Kluth, Kristine Fischer, Claudia Hube-Magg, Wenchao Li, Georgia Makrypidi-Fraune, Björn Wellge, Tim Mandelkow, Nicolaus F. Debatin, Doris Höflmayer, Maximilian Lennartz, Guido Sauter, Jakob R. Izbicki, Sarah Minner, Franziska Büscheck, Ria Uhlig, David Dum, Till Krech, Andreas M. Luebke, Corinna Wittmer, Frank Jacobsen, Eike-Christian Burandt, Stefan Steurer, Waldemar Wilczak & Andrea Hinsch. (2019) Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. Disease Markers 2019, pages 1-13.
Crossref
Crossref
Wenchao Li, Niclas C. Blessin, Ronald Simon, Martina Kluth, Kristine Fischer, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Björn Wellge, Tim Mandelkow, Nicolaus F. Debatin, Laura Pott, Doris Höflmayer, Maximilian Lennartz, Guido Sauter, Jakob R. Izbicki, Sarah Minner, Franziska Büscheck, Ria Uhlig, David Dum, Till Krech, Andreas M. Luebke, Corinna Wittmer, Frank Jacobsen, Eike Burandt, Stefan Steurer, Waldemar Wilczak & Andrea Hinsch. (2018) Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma. BMC Cancer 18:1.
Crossref
Crossref
Claudia Penafuerte, Luis Alberto Perez-Quintero, Valerie Vinette, Teri Hatzihristidis & Michel L. Tremblay. 2017. Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity
191
214
.